Codiak BioSciences (Codiak BioSciences) Scaled Net Operating Assets : 0.37 (As of Sep. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Codiak BioSciences Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Codiak BioSciences's operating assets for the quarter that ended in Sep. 2022 was $82.63 Mil. Codiak BioSciences's operating liabilities for the quarter that ended in Sep. 2022 was $34.19 Mil. Codiak BioSciences's Total Assets for the quarter that ended in Jun. 2022 was $132.71 Mil. Therefore, Codiak BioSciences's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2022 was 0.37.

Codiak BioSciences Scaled Net Operating Assets Historical Data

The historical data trend for Codiak BioSciences's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Codiak BioSciences Scaled Net Operating Assets Chart

Codiak BioSciences Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Scaled Net Operating Assets

0.03

-0.53

-0.10

0.26

Codiak BioSciences Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Scaled Net Operating Assets	Get a 7-Day Free Trial										-0.01	0.25	0.32	0.43	0.37

Competitive Comparison of Codiak BioSciences's Scaled Net Operating Assets

For the Biotechnology subindustry, Codiak BioSciences's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Codiak BioSciences's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Codiak BioSciences's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Codiak BioSciences's Scaled Net Operating Assets falls into.

Codiak BioSciences Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Codiak BioSciences's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2021 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2021 )
=	(Operating Assets (A: Dec. 2021 )	-	Operating Liabilities (A: Dec. 2021 ))	/	Total Assets (A: Dec. 2020 )
=	(94.732	-	55.19)	/	151.341
=	0.26

where

	Operating Assets		(A: Dec. 2021 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	171.67	-	76.938
=	94.732

	Operating Liabilities		(A: Dec. 2021 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	118.165	-	60.314	-	2.661
=	55.19

Codiak BioSciences's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2022 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Sep. 2022 )
=	(Operating Assets (Q: Sep. 2022 )	-	Operating Liabilities (Q: Sep. 2022 ))	/	Total Assets (Q: Jun. 2022 )
=	(82.634	-	34.19)	/	132.71
=	0.37

where

	Operating Assets		(Q: Sep. 2022 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	134.396	-	51.762
=	82.634

	Operating Liabilities		(Q: Sep. 2022 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	95.467	-	58.266	-	3.011
=	34.19

Codiak BioSciences Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Codiak BioSciences's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Codiak BioSciences (Codiak BioSciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Codiak BioSciences Inc (OTCPK:CDAKQ) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

35 Cambridge Park Drive, Suite 500, Cambridge, MA, USA, 02140

Website

https://www.codiakbio.com

Codiak BioSciences Inc is a development-stage biopharmaceutical company focused on the development of exosome-based therapeutics for the treatment of a wide spectrum of diseases with high unmet medical need. The company have utilized engEx Platform to generate a pipeline of engineered exosomes, aimed at treating a broad range of diseases, including oncology, neuro-oncology, neurology, neuromuscular disease, infectious disease and rare disease.

Executives

Yalonda Howze	officer: See Remarks	C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Sriram Sathyanarayanan	officer: Chief Scientific Officer	C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Nicole Barna	officer: See Remarks	C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Douglas E Williams	director, officer: President & CEO	C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799
Linda Bain	officer: Chief Financial Officer	C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Konstantin Konstantinov	officer: See Remarks	C/O CODIAK BIOSCIENCES, INC., 500 TECHNOLOGY SQUARE, 9TH FLOOR, CAMBRIDGE MA 02139
Arch Venture Fund Viii Overage, L.p.	10 percent owner	C/O ARCH VENTURE PARTNERS VIII, LLC, 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
David J Mauro	officer: Chief Medical Officer	36 TERRELL DRIVE, WASHINGTON CROSS PA 18977
Arundathy N. Pandite	director	1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Benny Sorensen	officer: See Remarks	C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Anne-virginie Eggimann	director	C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Jennifer J. Wheler	officer: Chief Medical Officer	C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Briggs Morrison	director	C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
Alaska Permanent Fund Corp	10 percent owner	801 WEST 10TH STREET, SUITE 302, JUNEAU AK 99801
Flagship Ventures Fund V, L.p.	10 percent owner	ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142